Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Technological Rehabilitation of Distal Sensorimotor Polyneuropathy in Diabetic Patients

21. marts 2014 opdateret af: Giovanni Taveggia

Technological Rehabilitation of Distal Sensorimotor Polyneuropathy in Diabetic

The investigators evaluated the effectiveness of the application of analysing treadmill, muscle strengthening and balance training compared to a control intervention in patients with diabetic neuropathy.

Studieoversigt

Detaljeret beskrivelse

Recent studies witnessed how physical exercise may interrupt the devastating decrease of muscle performance in DSP and further experiments are underway to find more exercises for the recovery of motor function impairment. In fact the rehabilitation treatment, that aims at reducing motor disability, preserving gait functions and preventing falling risks, is an interesting therapeutic approach. Literature recommends balance re-training exercises, muscle strengthening, selective stretching and retraining of motor activity.

New technologies produced in the recent decades different devices used in strengthening exercises (electromechanical dynamometers), balance recovery (balance platforms) and gait (analyzing treadmills) have visual feedbacks through which the patients may independently monitor accuracy and intensity of their exercises, being therefore strongly motivated and resulting in a high training intensity. These technologies are often used in rehabilitation of different patients, but are rarely employed for DSP.

The purpose of this case control study was to examine the effectiveness of the application of analysing treadmill, muscle strengthening and balance training compared to a control intervention in patients with diabetic neuropathy.

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

36

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Bergamo
      • Sarnico, Bergamo, Italien, 24067
        • Habilita, Ospedale di Sarnico

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 85 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • The participants need to have a history of diabetes mellitus type 2, >3 years, (i.e., time from the diagnosis or the beginning of first related signs or symptoms),
  • A diagnosis of Distal Sensorimotor Polyneuropathy associated,
  • Able to walk autonomously, eventually with a aid.

Exclusion Criteria:

  • Scoring less than 5 points on the Functional Independence Measure (FIM) (7) locomotion scale,
  • Presenting articular ankyloses, contractures, spasms with important locomotion effects,
  • Presenting bony instability affecting lower limb functionality (unconsolidated fractures, vertebral instability, severe osteoporosis),
  • In presence of attendant clinicopathological conditions contraindicating the rehabilitation treatment (respiratory insufficiency, cardiac/circulatory failure, osteomyelitis, phlebitis and different other conditions),
  • In presence of cutaneous lesions at lower limbs,
  • Scoring less than 22 points on the Mini Mental State Examination (MMSE),
  • Exhibit important behavioural diseases involving aggressivity or psychotic disorders.
  • Had received prior interventions for Distal Sensorimotor Polyneuropathy.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Technological Rehabilitation
Experimental group receives a treatment of: 20 minutes of analyzing treadmill with feedback focused on symmetry and length of stride; 20 minutes of isokinetic dynamometric muscle strengthening of flexor and extensor muscles of tibiotarsal joint; 20 minutes of balance retraining on dynamic balance platform. Each patient receives 20 sessions over a period of 4 weeks (5 sessions per week).

The length of stride of reference used during the exercise is personalized and depends on the height of patients. Each patient carries out the feedback for 20 minutes with the aim of generating the most symmetric and regular gait.

Patients, with the dynamometer, work on strengthening of flexor and extensor muscles with ankle speeds at 90°/sec and 120°/sec. The strengthening technique was performed twice for 10 minutes each time with a 1 minute rest between sets.

The session ends with a 20-minute feedback on dynamic balance platform by carrying out exercises in which they need to reach randomly appearing targets. Subjects begin with 12 minutes the first 4 sessions, progress to 16 minutes the next 2 sessions, then 18' (2 sessions), and finally 20', if able, during the last 4 sessions.

Andre navne:
  • Dynamometric isokinetic device: Biodex System 4,
  • Balance device: Biodex Balance System SD,
  • Analyzing treadmill: Biodex Gait Trainer 3.
Aktiv komparator: Control Rehabilitation
Control group receives the same number of treatment sessions of same duration as those in the experimental group: activities targeted to improve the endurance (instead of analyzing treadmill ), manual exercises of lower limb muscle strengthening, stretching exercises (instead of dynamometer), gait retraining on the floor for 20 minutes and static and dynamic balance exercises in upright position (instead of dynamic balance platform).
When needed, more than on e therapist are employed in the intervention for safety reasons.
Andre navne:
  • Manuel genoptræning med terapeuten.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change from Baseline of 6-minute walk test
Tidsramme: 1 day after the treatment

All evaluation procedures are performed by the same examiner who was blinded to the aims of the study and to which group the participants are allocated. The 6-minute walk test (6MWT) is used to assess endurance.

The 6MWT quantifies functional mobility based on the distance in meters traveled in six minutes. This outcome is a measure of endurance and is particularly significant to evaluate the possibility to perform continuative tasks, that are particularly important for the rehabilitation of diabetic patients and are relevant for an autonomous life. Subjects are instructed to walk at a comfortable speed and subjects neurological are able to use assistive devices.

1 day after the treatment
Change from Baseline of 10-metres walk test
Tidsramme: 1 day after the treatment

All evaluation procedures are performed by the same examiner who was blinded to the aims of the study and to which group the participants are allocated. The 10-metres walking test is used to assess gait speed.

The speed is quantified with the 10-metres walk test (TWT) over the ground. The gait speed measurement is performed over the middle 6 meters of the TWT and patients are asked to walk at their comfortable speed. Subjects are instructed to walk at a comfortable speed and subjects neurological are able to use assistive devices.

1 day after the treatment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Followup change from Baseline of 6-minute walk test
Tidsramme: 30 days after the treatment

All evaluation procedures are performed by the same examiner who was blinded to the aims of the study and to which group the participants are allocated. The 6-minute walk test (6MWT) is used to assess endurance.

The 6MWT quantifies functional mobility based on the distance in meters traveled in six minutes. This outcome is a measure of endurance and is particularly significant to evaluate the possibility to perform continuative tasks, that are particularly important for the rehabilitation of diabetic patients and are relevant for an autonomous life. Subjects are instructed to walk at a comfortable speed and subjects neurological are able to use assistive devices.

30 days after the treatment
Followup change from Baseline of 10-metres walk test
Tidsramme: 30 days after the treatment

All evaluation procedures are performed by the same examiner who was blinded to the aims of the study and to which group the participants are allocated. The 10-metres walking test is used to assess gait speed.

The speed is quantified with the 10-metres walk test (TWT) over the ground. The gait speed measurement is performed over the middle 6 meters of the TWT and patients are asked to walk at their comfortable speed. Subjects are instructed to walk at a comfortable speed and subjects neurological are able to use assistive devices.

30 days after the treatment
Change from Baseline of the Functional Independence Measure (FIM)
Tidsramme: 1 day after the treatment
1 day after the treatment
Change from Baseline of the Tinetti scale
Tidsramme: 1 day after the treatment
1 day after the treatment
Change from Baseline of the Resting Energy Expenditure (REE)
Tidsramme: 1 day after the treatment
1 day after the treatment
Change from Baseline of the Respiratory Rate (RR)
Tidsramme: 1 day after the treatment
1 day after the treatment
Change from Baseline of the Heart Rate (HR)
Tidsramme: 1 day after the treatment
1 day after the treatment
Change from Baseline of the oxygen saturation (SpO2)
Tidsramme: 1 day after the treatment
1 day after the treatment
Change from Baseline of the maximal oxygen consumption (VO2 max)
Tidsramme: 1 day after the treatment
1 day after the treatment
Change from Baseline of the expired minute volume (Ve)
Tidsramme: 1 day after the treatment
1 day after the treatment
Change from Baseline of the fraction of expired air that is oxygen (FeO2)
Tidsramme: 1 day after the treatment
1 day after the treatment
Change from Baseline of the Systolic Blood Pressure (SBP)
Tidsramme: 1 day after the treatment
1 day after the treatment
Change from Baseline of the Diastolic Blood Pressure (DBP)
Tidsramme: 1 day after the treatment
1 day after the treatment
Change from Baseline of the Glycated Hemoglobin (HbA1c)
Tidsramme: 1 day after the treatment
1 day after the treatment
Followup change from Baseline of the Functional Independence Measure (FIM)
Tidsramme: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the Tinetti scale
Tidsramme: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the Resting Energy Expenditure (REE)
Tidsramme: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the Respiratory Rate (RR)
Tidsramme: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the Heart Rate (HR)
Tidsramme: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the oxygen saturation (SpO2)
Tidsramme: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the maximal oxygen consumption (VO2 max)
Tidsramme: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the expired minute volume (Ve)
Tidsramme: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the fraction of expired air that is oxygen (FeO2)
Tidsramme: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the Systolic Blood Pressure (SBP)
Tidsramme: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the Diastolic Blood Pressure (DBP)
Tidsramme: 30 days after the treatment
30 days after the treatment
Followup change from Baseline of the Glycated Hemoglobin (HbA1c)
Tidsramme: 30 days after the treatment
30 days after the treatment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Giovanni Taveggia, MD, Habilita, Ospedale di Sarnico

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. september 2013

Primær færdiggørelse (Faktiske)

1. november 2013

Studieafslutning (Faktiske)

1. november 2013

Datoer for studieregistrering

Først indsendt

14. august 2013

Først indsendt, der opfyldte QC-kriterier

17. august 2013

Først opslået (Skøn)

21. august 2013

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

24. marts 2014

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

21. marts 2014

Sidst verificeret

1. marts 2014

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • Habilita-RAR-02
  • 201206180007491711110 (Anden identifikator: Bioethic board)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Diabetiske neuropatier

Kliniske forsøg med Technological Rehabilitation

Abonner